Targeting the role of N-terminal methionine processing enzymes in Mycobacterium tuberculosis

Omonike A. Olaleye, William R. Bishai, Jun O. Liu

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The discovery of anti-tuberculosis agents that target new pathways is crucial for effective short-term TB therapy that will limit the development of resistance. The clinical significance of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis, latent TB and Human Immunodeficiency Virus co-infection in tuberculosis patients have made the development of new antimycobacterials more imperative. A better understanding of the major pathways that are involved in the pathogenesis, survival, and dormancy of Mtb will aid in the identification of new drug targets. Here, we review the N-terminal methionine excision (NME) pathway as a potential drug target during host infection with M. tuberculosis. The removal of the N-terminal methionine is a requirement for some proteins prior to post-translational modifications and processing. Therefore, an understanding of the physiological relevance of the two families of enzymes at the center of NME - peptide deformylases and methionine aminopeptidases - has the prospect of adding novel targets and antimycobacterials to the pipeline.

Original languageEnglish (US)
Pages (from-to)S55-S59
Issue numberSUPPL.1
StatePublished - Dec 2009


  • Methionine aminopeptidase (MetAP)
  • Mycobacterium tuberculosis (Mtb)
  • N-Terminal methionine excision (NME)
  • Peptide deformylase (PDF)
  • Tuberculosis (TB)

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Infectious Diseases
  • Microbiology (medical)


Dive into the research topics of 'Targeting the role of N-terminal methionine processing enzymes in Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this